Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Sitagliptin (Januvia®) 25 and 50 mg tablets are recommended as an option for use within NHS Wales for the improvement of glycaemic control in type 2 diabetes mellitus patients with moderate renal impairment (CrCl ≥ 30 to < 50 ml/min), severe renal impairment (CrCl < 30 ml/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis. |
|||
|
|||
Medicine details |
|||
| Medicine name | sitagliptin (Januvia®) | ||
| Formulation | 25 mg film-coated tablet, 50 mg film-coated tablet | ||
| Reference number | 1655 | ||
| Indication | Improvement of glycaemic control in type 2 diabetes mellitus patients with moderate renal impairment (CrCl ≥ 30 to < 50 mL/min), severe renal impairment (CrCl < 30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis |
||
| Company | Merck Sharp & Dohme Ltd | ||
| BNF chapter | Endocrine system | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 2912 | ||
| NMG meeting date | 10/07/2012 | ||
| AWMSG meeting date | 12/09/2012 | ||
| Ratification by Welsh Government | 25/10/2012 | ||
| Date of issue | 25/10/2012 | ||
| Date of last review | 30/09/2016 | ||